Second Blog Post In Series Examines China’s History Of Artemisinin Drug Development

Council on Foreign Relation’s “Asia Unbound”: Artemisinin’s Rocky Road to Globalization: Part II
In part two of his series on anti-malarial artemisinin drugs, Yanzhong Huang, CFR senior fellow for global health, explores the challenges China faced in marketing its artemisinin-based combination therapies worldwide. “…The 2004-2006 artemisinin bubble nevertheless has not deterred Chinese pharmaceutical firms from pursuing its globalization strategy. Supported by the state, Chinese pharmaceutical firms since 2007 have become even more aggressive in promoting their anti-malarial products globally. But how successful are their efforts? This will be the subject of my next blog post” (3/9).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.